Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.55 |
| ▸ | WNT3A | P56704 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4085995 | 0.88 | SMN1; SMN2 (0.54) | ALDH1A1HPGDHSD17B10CYP1A2CYP2C19 | |
| SCHEMBL18755183 | 0.87 | PDE4D (0.54) | ALDH1A1HPGDCTNNB1WNT3AKMT2A | |
| SCHEMBL8217525 | 0.86 | HSD17B10 (0.49) | ALDH1A1HPGDHSD17B10CYP1A2CYP2C19 | |
| SCHEMBL4090943 | 0.86 | HSD17B10 (0.53) | ALDH1A1HPGDHSD17B10CYP1A2CYP2C19 | |
| SCHEMBL29923058 | 0.85 | CTNNB1 (0.73) | ALDH1A1HPGDHSD17B10CYP1A2CYP2C19 | |
| SCHEMBL1527427 | 0.85 | CTNNB1 (0.73) | ALDH1A1HPGDHSD17B10CYP1A2CYP2C19 | |
| SCHEMBL9120028 | 0.84 | CTNNB1 (0.49) | ALDH1A1HPGDHSD17B10CYP1A2CYP2C19 | |
| SCHEMBL10758599 | 0.83 | PTPN1 (0.51) | ALDH1A1HPGDHSD17B10CYP1A2CYP2C19 | |
| SCHEMBL5188941 | 0.83 | ALDH1A1 (0.59) | ALDH1A1HPGDHSD17B10CYP1A2CYP2C19 | |
| SCHEMBL5495178 | 0.83 | CTNNB1 (0.60) | ALDH1A1HPGDHSD17B10CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048258-A1 | Amide Compound | TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20090048258-A1 | Amide Compound | TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20090048258-A1 | Amide Compound | TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1845081-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048258-A1 | Amide Compound | DLAT, DGAT1, DGAT2 | ALDH1A1 435/4885HPGD 1713/4885HSD17B10 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.